Cargando…

Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer

BACKGROUND: Microsatellite unstable colorectal cancers (MSI+ CRCs) expressing PD-L1, respond to anti-PD-1 or anti-PD-L1 checkpoint blockade, whereas microsatellite-stable tumors do not respond the same. Our aim was to examine how the immune landscape relates to different aspects of the CRC’s biology...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaravinos, Apostolos, Roufas, Constantinos, Nagara, Majdi, de Lucas Moreno, Beatriz, Oblovatskaya, Maria, Efstathiades, Christodoulos, Dimopoulos, Christos, Ayiomamitis, Georgios D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6701076/
https://www.ncbi.nlm.nih.gov/pubmed/31429779
http://dx.doi.org/10.1186/s13046-019-1372-z
_version_ 1783444991978242048
author Zaravinos, Apostolos
Roufas, Constantinos
Nagara, Majdi
de Lucas Moreno, Beatriz
Oblovatskaya, Maria
Efstathiades, Christodoulos
Dimopoulos, Christos
Ayiomamitis, Georgios D.
author_facet Zaravinos, Apostolos
Roufas, Constantinos
Nagara, Majdi
de Lucas Moreno, Beatriz
Oblovatskaya, Maria
Efstathiades, Christodoulos
Dimopoulos, Christos
Ayiomamitis, Georgios D.
author_sort Zaravinos, Apostolos
collection PubMed
description BACKGROUND: Microsatellite unstable colorectal cancers (MSI+ CRCs) expressing PD-L1, respond to anti-PD-1 or anti-PD-L1 checkpoint blockade, whereas microsatellite-stable tumors do not respond the same. Our aim was to examine how the immune landscape relates to different aspects of the CRC’s biology, including neoepitope burden. METHODS: We used TCGA data to stratify patients based on a cytolytic T-cell activity expression index and correlated immune cytolytic activity (CYT) with mutational, structural, and neoepitope features of each tumor sample. The expression of several immune checkpoints was verified in an independent cohort of 72 CRC patients, relative to their MSI status, using immunohistochemistry and RT-qPCR. RESULTS: CRC exhibits a range of intertumoral cytolytic T-cell activity, with lower cytolytic levels in the tumor, compared to the normal tissue. We separated CRC patients into CYT-high and CYT-low subgroups. High cytolytic activity correlated with increased mutational load in colon tumors, the count of MHC-I/−II classically defined and alternatively defined neoepitopes, high microsatellite instability and deregulated expression of several inhibitory immune checkpoints (VISTA, TIGIT, PD-1, IDO1, CTLA-4, and PD-L1, among others). Many immune checkpoint molecules (IDO1, LAG3, TIGIT, VISTA, PD-1, PD-L1 and CTLA-4) expressed significantly higher in MSI+ CRCs compared to MSS tumors. The expression of Treg markers was also significantly higher in CYT-high tumors. Both individual and simultaneous high levels of CTLA-4 and PD-L1 had a positive effect on the patients’ overall survival. On the reverse, simultaneous low expression of both genes led to a significant shift towards negative effect. Assessed globally, CYT-low CRCs contained more recurrent somatic copy number alterations. PD-L1 protein was absent in most samples in the independent cohort and stained lowly in 33% of MSI CRCs. PD-L1+ CRCs stained moderately for CD8 and weakly for FOXP3. CYT-high colon tumors had higher TIL load, whereas CYT-high rectum tumors had higher TAN load compared to their CYT-low counterparts. CONCLUSIONS: Overall, we highlight the link between different genetic events and the immune microenvironment in CRC, taking into consideration the status of microsatellite instability. Our data provide further evidence that MSI+ and CYT-high tumors are better candidates for combinatorial checkpoint inhibition. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13046-019-1372-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6701076
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-67010762019-08-26 Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer Zaravinos, Apostolos Roufas, Constantinos Nagara, Majdi de Lucas Moreno, Beatriz Oblovatskaya, Maria Efstathiades, Christodoulos Dimopoulos, Christos Ayiomamitis, Georgios D. J Exp Clin Cancer Res Research BACKGROUND: Microsatellite unstable colorectal cancers (MSI+ CRCs) expressing PD-L1, respond to anti-PD-1 or anti-PD-L1 checkpoint blockade, whereas microsatellite-stable tumors do not respond the same. Our aim was to examine how the immune landscape relates to different aspects of the CRC’s biology, including neoepitope burden. METHODS: We used TCGA data to stratify patients based on a cytolytic T-cell activity expression index and correlated immune cytolytic activity (CYT) with mutational, structural, and neoepitope features of each tumor sample. The expression of several immune checkpoints was verified in an independent cohort of 72 CRC patients, relative to their MSI status, using immunohistochemistry and RT-qPCR. RESULTS: CRC exhibits a range of intertumoral cytolytic T-cell activity, with lower cytolytic levels in the tumor, compared to the normal tissue. We separated CRC patients into CYT-high and CYT-low subgroups. High cytolytic activity correlated with increased mutational load in colon tumors, the count of MHC-I/−II classically defined and alternatively defined neoepitopes, high microsatellite instability and deregulated expression of several inhibitory immune checkpoints (VISTA, TIGIT, PD-1, IDO1, CTLA-4, and PD-L1, among others). Many immune checkpoint molecules (IDO1, LAG3, TIGIT, VISTA, PD-1, PD-L1 and CTLA-4) expressed significantly higher in MSI+ CRCs compared to MSS tumors. The expression of Treg markers was also significantly higher in CYT-high tumors. Both individual and simultaneous high levels of CTLA-4 and PD-L1 had a positive effect on the patients’ overall survival. On the reverse, simultaneous low expression of both genes led to a significant shift towards negative effect. Assessed globally, CYT-low CRCs contained more recurrent somatic copy number alterations. PD-L1 protein was absent in most samples in the independent cohort and stained lowly in 33% of MSI CRCs. PD-L1+ CRCs stained moderately for CD8 and weakly for FOXP3. CYT-high colon tumors had higher TIL load, whereas CYT-high rectum tumors had higher TAN load compared to their CYT-low counterparts. CONCLUSIONS: Overall, we highlight the link between different genetic events and the immune microenvironment in CRC, taking into consideration the status of microsatellite instability. Our data provide further evidence that MSI+ and CYT-high tumors are better candidates for combinatorial checkpoint inhibition. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13046-019-1372-z) contains supplementary material, which is available to authorized users. BioMed Central 2019-08-20 /pmc/articles/PMC6701076/ /pubmed/31429779 http://dx.doi.org/10.1186/s13046-019-1372-z Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Zaravinos, Apostolos
Roufas, Constantinos
Nagara, Majdi
de Lucas Moreno, Beatriz
Oblovatskaya, Maria
Efstathiades, Christodoulos
Dimopoulos, Christos
Ayiomamitis, Georgios D.
Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer
title Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer
title_full Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer
title_fullStr Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer
title_full_unstemmed Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer
title_short Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer
title_sort cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6701076/
https://www.ncbi.nlm.nih.gov/pubmed/31429779
http://dx.doi.org/10.1186/s13046-019-1372-z
work_keys_str_mv AT zaravinosapostolos cytolyticactivitycorrelateswiththemutationalburdenandderegulatedexpressionofimmunecheckpointsincolorectalcancer
AT roufasconstantinos cytolyticactivitycorrelateswiththemutationalburdenandderegulatedexpressionofimmunecheckpointsincolorectalcancer
AT nagaramajdi cytolyticactivitycorrelateswiththemutationalburdenandderegulatedexpressionofimmunecheckpointsincolorectalcancer
AT delucasmorenobeatriz cytolyticactivitycorrelateswiththemutationalburdenandderegulatedexpressionofimmunecheckpointsincolorectalcancer
AT oblovatskayamaria cytolyticactivitycorrelateswiththemutationalburdenandderegulatedexpressionofimmunecheckpointsincolorectalcancer
AT efstathiadeschristodoulos cytolyticactivitycorrelateswiththemutationalburdenandderegulatedexpressionofimmunecheckpointsincolorectalcancer
AT dimopouloschristos cytolyticactivitycorrelateswiththemutationalburdenandderegulatedexpressionofimmunecheckpointsincolorectalcancer
AT ayiomamitisgeorgiosd cytolyticactivitycorrelateswiththemutationalburdenandderegulatedexpressionofimmunecheckpointsincolorectalcancer